common.study.topics.clinical

Treatment of Advanced Solid and Hematologic Cancers

common.study.values.description

“A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers”

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Parts B and C), first-in-human clinical study of CC-95251 in subjects with advanced cancers.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - CC-95251

CC-95251 administered by IV (intravenous) infusion.

Drug - Rituximab

Rituximab administered by IV (intravenous) infusion.

Drug - Cetuximab

Cetuximab administered by IV (intravenous) infusion.

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers

common.study.values.clinical-trial-id

NCT03783403

participant.views.study.view.id

aM8oQe